REGENEREX PHARMA, INC. 8-K

What Happened

• Regenerex Pharma, Inc. filed an 8-K reporting that Chief Financial Officer Kenneth Perry was placed on paid administrative suspension effective March 31, 2026 and, following a Committee review, the Independent Board approved termination of his employment for "Cause" with notice delivered May 2, 2026.
• The Board’s Governance and Nominating Committee (three independent advisors) reviewed audit-related findings, Board records, and documented communications and recommended termination. The independent directors met on April 27, 2026 (two of three present); the CEO recused from related deliberations.
• On April 1, 2026 the Board appointed Don E. Ray as Interim Chief Financial Officer for an initial 90-day term.

Key Details

• Administrative suspension with pay began: March 31, 2026.
• Committee determination of "Cause" and Board decision: April 27, 2026; termination notice delivered: May 2, 2026.
• Committee composition: three independent advisors; review materials included audit-related findings and Board records.
• Interim CFO appointment date and term: Don E. Ray appointed April 1, 2026 for an initial 90 days.

Why It Matters

• A CFO suspension and subsequent termination for Cause is a material leadership change that directly affects oversight of financial reporting and controls. The Committee’s review citing audit-related findings highlights that the issue involved the company’s financial processes or records.
• The appointment of an interim CFO provides immediate leadership continuity, but investors should watch for further disclosures about the underlying findings, any impacts on previously reported financials, and the company’s search for a permanent CFO.